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Disclaimer:Thisguidelineisdesignedprimarilyasaneducationalresourceformedicalgeneticistsandotherhealthcareproviders
to help them provide quality medical genetic services. Adherence to this guideline does not necessarily assure a successful medical
outcome. This guideline should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and
tests that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, the
geneticistshouldapplyhisorherownprofessionaljudgmenttothespecificclinicalcircumstancespresentedbytheindividualpatient
or specimen. It may be prudent, however, to document in the patient’s record the rationale for any significant deviation from this
guideline. Genet Med 2008:10(1):54–56.
Diseases commonly grouped together as “Jewish Genetic
Disorders” (JGDs) range in incidence from 1/900 to 1/40,000
intheJewishcommunity,specificallythoseindividualsofAsh-
kenazi (eastern European) heritage. Although some of these
disorders in isolation would be considered rare, the overall
carrierrateinthispopulationissignificant,withbetween1in4
and 1 in 5 Ashkenazi Jews carrying a mutation for any one of
these disorders. Because of genetic drift in combination with
historicalandsocialfactors,certainautosomalrecessivedisor-
ders have been found to occur at a higher incidence (e.g., Tay-
Sachs disease) or almost exclusively in this population (e.g.,
familial dysautonomia) whereas other disorders may be as
common as in other high risk groups (e.g., cystic fibrosis).
However, the commonality for JGDs is that all exhibit the
founder mutation phenomenon whereby only 1–3 mutations
account for the vast majority of deleterious alterations found
in this specific population.
Over 30 years ago, the development of an accurate and reli-
able biochemical test led to a remarkably successful commu-
nitycarrierscreeningprogramforTay-Sachsdisease.Thesub-
sequent widespread adoption of Tay-Sachs carrier screening
resulted in a significant drop in this disease among the Ash-
kenazi Jewish population. Today, the vast majority of children
born with Tay-Sachs disease have non-Jewish parents. Ad-
vances in our understanding of the molecular biology of Tay-
Sachs disease and other Jewish genetic disorders have resulted
in the identification of many of the “founder” mutations
present in this population (Table 1).
As technology has improved, our ability to perform carrier
screening for an increasing number of disorders has likewise
expanded. However, there has been debate as to which disor-
ders should be included in preconception/prenatal carrier
screeningpanelsandwhatcriteriashouldbeusedtodetermine
how this selection is made. In addition, it is important to take
into account the needs of the community for which screening
is intended (see commentary in this issue, page 33). Although
there is no definitive mechanism whereby any individual or
organizationcanspeakforapopulationasawhole,experience
both in the United States and Israel points to overall accep-
tanceofcarrierscreeningintheJewishpopulationifdonewith
sensitivity and respect for cultural and religious differences.
Several support groups have taken it upon themselves to edu-
catethecommunityandprofessionalsabouttheneedforcom-
prehensive testing and prevention. The ultra-orthodox Dor
Yeshorimprogramhasadvocatedforbroad-basedtestingforde-
cades and the Central Conference of American Rabbis, the rab-
binicarmoftheReformMovement,NorthAmerica’slargestJew-
ish denomination, has passed a resolution urging all Reform
Rabbis to counsel prospective couples on the availability of test-
ing.Thus,thecommunityfocusisontheaccuracyofthetestand
itsabilitytopreventsignificantdiseaseasopposedto“cherrypick-
ing” disorders based on overall incidence or rarity.
This document seeks to provide guidance to clinicians re-
garding prenatal/preconception carrier screening for Ash-
kenazi Jewish individuals; however, new discoveries and tech-
nological advances will inevitably result in the availability of
additional tests and revised recommendations in the future.
Recommendations
1. Werecommendthatcarrierscreeningforcysticfibrosis,Cana-
van disease, familial dysautonomia, and Tay-Sachs disease be
offeredtoallAshkenaziJewswhoarepregnantorconsidering
pregnancy,accordingtocurrentAmericanCollegeofMedical
Genetics and/or the American College of Obstetricians and
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mend that carrier screening be offered for Fanconi anemia
(Group C), Niemann-Pick (Type A), Bloom syndrome, mu-
colipidosisIV,andGaucherdisease.Carrierscreeningforthese
disorders should include testing for the specific mutations
listed in Table 1, which will result in a carrier detection rate 
95% for most disorders. As a result, even in disorders that are
relativelylesscommon,expectedmutation-specificcarrierfre-
quencies are relatively high.
2. Additional disorders will be considered for addition to this
panel based on the following:
a. Thenaturalhistoryofthedisordershouldbewellunder-
stood and carry a potential for significant morbidity
and/or mortality in the homozygous or compound het-
erozygous state.
b. Based on available scientific literature there should be
either  90% detection rate or an allele frequency of
1% in the Ashkenazi Jewish population.
Table 1
Jewish genetic disorders for which testing should be offered (see Technical Standards and Guidelines for Reproductive Screening in the Ashkenazi
Jewish Population, Page 57)
Disease name Carrier frequency Common mutations
Allele frequency among
affected Ashkenazi
Jewish patients (%)
Expected Ashkenazi Jewish
mutation-specific carrier
frequency (%)
a
Familial dysautonomia 1 in 31 25076T3C 98.7 3.18
R696P 0.7 0.02
Detection rate: 99
Tay-Sachs disease 1 in 31 1278insTATC 81.6 2.63
14211G3C 11.5 0.37
G269S (mild) 5.8 0.19
Other 1.1
Detection rate: 92–99
b
Canavan disease 1 in 41 E285A 83.3 2.03
Y231X 14.1 0.34
Detection rate: 97.4
Fanconi anemia group C 1 in 89 IVS44A3T 99 1.12
Detection rate: 99
Niemann-Pick type A 1 in 90 R496L 43 0.47
L302P 29 0.32
fsP330 25 0.28
Detection rate: 97
Bloom syndrome 1 in 107 2281del6ins7 99 0.93
Detection rate: 99
Mucolipidosis IV 1 in 127 IVS3–2A3G 77 0.61
Del6.4kb 18 0.14
Detection rate: 95
Gaucher disease Type I 1 in 18 N370S 86 4.8
84GG 5.6 0.31
L444P 2.1 0.12
IVS21G3A 0.9 0.05
Detection rate: 89–94.6
c
aCarrier frequency (Column 2)  Allele frequency among affected Ashkenazi Jewish patients (Column 4).
b98% is reflective of a homogenous Ashkenazi background where all four grandparents are likely of Ashkenazi Jewish heritage. 92% may be more reflective of more
diverse populations.
c89% is based on the allele frequencies in Ashkenazi Gaucher disease Type 1 patients. 94.6% is adjusted to account for the presence of N370S homozygous
asymptomatic individuals who would not be identified by screening affected patients.
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these thresholds in the future, they appear to be rational
and appropriate at this time. As always, any such testing
should meet the highest standards of quality as detailed
in the companion laboratory guidelines.
3. Theofferingofsuchtestingshouldideallytakeplacebefore
pregnancy, thereby giving individuals time to make appro-
priate reproductive decisions based on their own personal
choices and cultural backgrounds. Currently, the majority
of testing takes place in the primary care obstetrical setting
andnotinthemedicalgeneticspecialtyenvironment.How-
ever, regardless of the clinical setting, adequate counseling
should be provided to anyone considering testing so that
choices are truly “informed.” Counseling should include
the following:
a. A general description of the disorders should be pro-
vided. Audiovisual materials are available and bro-
chures, videos etc., can supplement the discussion.
b. Whereas some of these disorders are associated with
consistent symptoms and findings, others have impre-
cise phenotype/genotype correlations with the possibil-
ity of mild disease.
c. Although detection rates are excellent overall, counsel-
ing must include an understanding that in the case of a
negative test, a residual risk remains.
d. A carrier of a gene mutation for an autosomal recessive
disorder is a healthy individual who is not at risk of de-
veloping the disease but has a risk of passing the gene
mutation to his/her offspring.
e. The success of the Tay-Sachs screening program has re-
sulted in the possible misperception that the Tay-Sachs
gene is no longer present in the Ashkenazi Jewish com-
munity. Because a carrier is asymptomatic, screening by
necessity should occur in every generation. Further-
more, some individuals are aware that they or their par-
ents may have been tested for Tay-Sachs disease in the
past, possibly through community testing programs. If
documentation is not available, it is appropriate to offer
repeat testing.
f. Formalgeneticcounselingandmedicalgeneticconsulta-
tion should be readily available to anyone desiring this
service.
4. IfonlyonememberofacoupleisofAshkenaziJewishback-
ground, testing should still be offered. Ideally, the Jewish
member of the couple should be tested first. If the Jewish
partner has a positive test result, the other partner (regard-
less of background) should be screened for that particular
disorder. In the case of Tay-Sachs disease, testing can be
performed using the biochemical assay, which has an
excellent detection rate regardless of ethnic or racial
background.Themutationdetectionrateandcarrierfre-
quency among different ethnic/racial groups is known
for cystic fibrosis; however, for the other disorders, a
discussion should include the lack of a precise residual
risk in the case where the non-Jewish partner is negative
on mutation analysis.
5. Generally, individuals self-identify themselves as Jewish
and whether or not they are of eastern European origin.
One Jewish grandparent is sufficient to offer testing. How-
ever, if someone is unsure as to their precise lineage, it is
recommended to offer testing. At this time, there is no spe-
cific panel of tests available for Jews from non-Ashkenazi
background. However, a proper family history and ethnic
origin should still be obtained and appropriate testing of-
fered (e.g., hemoglobinopathy screening for those from the
Mediterranean basin).
6. In the case where someone is identified as a carrier, genetic
counseling should be readily available to discuss the find-
ingsandpossiblereproductiveoptions.Furthermore,adis-
cussion regarding the importance of genetic counseling for
other family members should be stressed. Although the
providercannotcontactfamilymembersdirectly,theindi-
vidualshouldbeencouragedtodiscussthefindingswithhis
or her family if possible and appropriate.
7. At present, many laboratories offer these tests as a panel,
testingforseveraldisordersasagroup,inasinglemultiplex
assay. This approach is practical from a technical and cost
standpoint.However,theethicalconceptofrespectforper-
sons necessitates that physicians only order tests for those
diseases that have been consented to by the patient. If a
patient does not provide informed consent for all tests in-
cludedinamultiplexpanel,thentherequestedtestsshould
be ordered individually.
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